|
- Updated Guidelines on the Treatment of Drug-Susceptible and Drug . . .
The panel recommends a six-month treatment regimen (BPaL) of bedaquiline (B), pretomanid (P), and linezolid (L) for people aged 14 years or older with rifampin-resistant pulmonary TB disease and fluoroquinolone resistance or intolerance These regimens are also treatment options for people with an intolerance of rifampin
- Updates to Provisional Guidance for the Use of Pretomanid as Part of a . . .
Today, CDC released updates to the 2022 "Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease " Updates include: A recommendation for an initial linezolid dose of 600 mg when using the BPaL regimen in the treatment of adults,
- Treatment for Drug-Resistant Tuberculosis Disease - CDC
People initiating treatment for MDR or rifampin-resistant TB but ineligible for BPaL (e g , resistance or intolerance to bedaquiline, pretomanid, or linezolid; severe extrapulmonary TB; pregnant; lactating; or aged less than 14 years) can receive an individualized regimen based on the 2019 guidelines Treatment of Drug-Resistant Tuberculosis
- Clinical Guidelines | Tuberculosis (TB) | CDC
This page provides a list of selected clinical guidelines related to tuberculosis (TB) topics Guidelines are sorted by topics: testing and diagnosis, treatment, drug resistance, infection control, and specific populations
- Dear Colleague Letters | Tuberculosis (TB) | CDC
Updates to Provisional Guidance for the Use of Pretomanid as Part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease CDC updated the 2022 Provisional Guidance for the BPaL Regimen to Treat Drug-resistant TB Disease
- Connections Newsletter (Issue 22-1) | CDC NCHHSTP
CDC's Division of Tuberculosis Elimination (DTBE) – Although not in 2021, Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease is now available The new guidance contains considerations for clinicians, dosing and administration
- Notes from the Field: Supply Interruptions of First . . .
Investigation and Outcomes A web-based Research Electronic Data Capture (REDCap) survey (version 13 1 30; Vanderbilt University) was distributed to TB controllers and program managers of all 61 California TB programs †† to assess delays in availability §§ and unavailability of oral first- and second-line TB drugs during the preceding 12 months
- Tuberculosis | Yellow Book | CDC
More recently, for persons aged 14 years and older who have rifampin-resistant or multidrug-resistant pulmonary TB, a 6-month all-oral regimen of bedaquiline, pretomanid, and linezolid is recommended, with moxifloxacin added if the TB is fluoroquinolone-susceptible
|
|
|